Stocktoria
XOMA Royalty Corp XOMA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1986-06-06
XOMA Royalty Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.1M | $28.5M | $4.8M | $6.0M | $38.2M | $29.4M | $18.4M | $5.3M | $52.7M | $5.6M |
| R&D expense | $1.7M | $2.9M | $143,000 | $153,000 | $171,000 | $170,000 | $1.3M | $1.7M | $7.9M | $44.2M |
| SG&A expense | — | — | — | — | — | — | — | — | — | $18.3M |
| Operating income | $11.4M | -$40.0M | -$41.8M | -$17.4M | $17.5M | $12.4M | -$3.9M | -$16.9M | $17.0M | -$61.6M |
| Income tax | $103,000 | -$5.7M | $0 | -$15,000 | $91,000 | -$1.5M | $0 | -$98,000 | $1.7M | $0 |
| Net income | $31.7M | -$13.8M | -$40.8M | -$17.1M | $15.8M | $13.3M | -$2.0M | -$13.3M | $14.6M | -$53.5M |
| EPS (diluted) | $1.46 | $-1.65 | $-4.04 | $-1.98 | $0.65 | $0.78 | $-0.23 | $-1.59 | $0.73 | $-8.89 |
| Operating cash flow | $2.9M | -$13.7M | -$18.2M | -$12.9M | $22.7M | $10.1M | -$285,000 | -$12.6M | $2.7M | -$33.7M |
| Free cash flow | — | -$13.8M | -$18.2M | — | — | $10.1M | — | -$12.7M | $2.7M | -$33.7M |
| Cash & equivalents | $82.9M | $101.7M | $153.3M | $57.8M | $93.3M | — | — | $45.8M | $43.5M | $25.7M |
| Total assets | $272.7M | $221.3M | $234.3M | $140.4M | $166.6M | $125.3M | $95.7M | $63.8M | $44.9M | $28.7M |
| Total liabilities | $168.7M | $139.4M | $145.6M | $16.4M | $24.7M | $38.9M | $51.7M | $45.0M | $39.1M | $75.9M |
| Shareholders' equity | $83.9M | $61.9M | $88.7M | $124.0M | $141.9M | $86.4M | $44.0M | $18.8M | $5.8M | -$47.2M |
Growth · year-over-year · Revenue CAGR 28.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +83.1% | +498.7% | -21.1% | -84.2% | +29.9% | +60.0% | +246.7% | -89.9% | +847.0% | -90.0% |
| Net income growth | — | — | — | -208.3% | +18.8% | — | — | -191.4% | — | — |
| EPS growth | — | — | — | -404.6% | -16.7% | — | — | -317.8% | — | — |
| Free cash flow growth | — | — | — | — | — | — | — | -572.4% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.